DE2120426A1 - Varicellavaccine - Google Patents
VaricellavaccineInfo
- Publication number
- DE2120426A1 DE2120426A1 DE19712120426 DE2120426A DE2120426A1 DE 2120426 A1 DE2120426 A1 DE 2120426A1 DE 19712120426 DE19712120426 DE 19712120426 DE 2120426 A DE2120426 A DE 2120426A DE 2120426 A1 DE2120426 A1 DE 2120426A1
- Authority
- DE
- Germany
- Prior art keywords
- virus
- varicella
- vaccine
- tissue culture
- humans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940021648 varicella vaccine Drugs 0.000 title claims description 3
- 241000700605 Viruses Species 0.000 claims description 28
- 229960005486 vaccine Drugs 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 241000282693 Cercopithecidae Species 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000001840 diploid cell Anatomy 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000002381 testicular Effects 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 230000005875 antibody response Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 16
- 238000003306 harvesting Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 201000006082 Chickenpox Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000036758 Postinfectious cerebellitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037867 Rash macular Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010074254 Varicella zoster pneumonia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3276970A | 1970-04-28 | 1970-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2120426A1 true DE2120426A1 (de) | 1971-11-11 |
Family
ID=21866708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712120426 Pending DE2120426A1 (de) | 1970-04-28 | 1971-04-26 | Varicellavaccine |
Country Status (11)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043847A4 (en) * | 1980-01-25 | 1982-07-06 | Wistar Inst | HIGHLY ATTENUED CHICKENPOX VIRUS VACCINE AND PRODUCTION THEREOF. |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2952825B1 (fr) | 2009-11-24 | 2012-05-25 | Goaster Jacqueline Le | Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2 |
-
1971
- 1971-03-16 NL NL7103524A patent/NL7103524A/xx unknown
- 1971-04-19 IL IL36649A patent/IL36649A0/xx unknown
- 1971-04-20 AU AU27888/71A patent/AU2788871A/en not_active Expired
- 1971-04-23 AT AT354771A patent/AT303965B/de not_active IP Right Cessation
- 1971-04-26 DE DE19712120426 patent/DE2120426A1/de active Pending
- 1971-04-26 GB GB01385/71A patent/GB1293310A/en not_active Expired
- 1971-04-26 ES ES390603A patent/ES390603A1/es not_active Expired
- 1971-04-27 BE BE766333A patent/BE766333A/xx unknown
- 1971-04-27 ZA ZA712711A patent/ZA712711B/xx unknown
- 1971-04-27 HU HUME1354A patent/HU163131B/hu unknown
- 1971-04-27 FR FR7114922A patent/FR2092100B1/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043847A4 (en) * | 1980-01-25 | 1982-07-06 | Wistar Inst | HIGHLY ATTENUED CHICKENPOX VIRUS VACCINE AND PRODUCTION THEREOF. |
Also Published As
| Publication number | Publication date |
|---|---|
| AT303965B (de) | 1972-12-27 |
| BE766333A (fr) | 1971-10-27 |
| ES390603A1 (es) | 1974-04-01 |
| GB1293310A (en) | 1972-10-18 |
| FR2092100A1 (enrdf_load_stackoverflow) | 1972-01-21 |
| FR2092100B1 (enrdf_load_stackoverflow) | 1974-08-30 |
| IL36649A0 (en) | 1971-06-23 |
| ZA712711B (en) | 1972-12-27 |
| HU163131B (enrdf_load_stackoverflow) | 1973-06-28 |
| NL7103524A (enrdf_load_stackoverflow) | 1971-11-01 |
| AU2788871A (en) | 1972-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69215355T2 (de) | Stabilisierter Varizella-Lebendimpfstoff | |
| DE3911442A1 (de) | Impfstoff-praeparation | |
| DE2516274C2 (de) | Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes | |
| EP0173241B1 (de) | Vakzine zur Behandlung der Harnwegsinfektionen | |
| DE2423129C2 (de) | Temperaturempfindliche, nicht-pathogene Rinder-Adeno-Virus-Mutantenstämme, Verfahren zu ihrer Herstellung und diese Virusstämme enthaltender Lebendimpfstoff | |
| DE2553998C2 (de) | Mumpsvaccin und Verfahren zu seiner Herstellung | |
| DE2362067C2 (de) | Temperaturempfindliche, nicht-pathogene, infektiöse Rinder-Rhinotracheitis-Virusstämme, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Lebendimpfstoffen | |
| DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
| DE2655691C2 (de) | Temperaturempfindliche, vermehrungsfähige, nicht pathogene Varicella-Zoster-Viren, Verfahren zu ihrer Herstellung und diese Viren enthaltende Lebendvaccine | |
| DE69306934T2 (de) | Geflügelkrankheit verursachende neue bakterie und daraus stammender impfstoff | |
| DE2120426A1 (de) | Varicellavaccine | |
| DE4104728C2 (de) | Verwendung eines Bakterien-Lysats zur Behandlung der atopischen Dermatitis | |
| DE3034238A1 (de) | Impfstoff zur bekaempfung der newcastle-krankheit und verfahren zur herstellung derselben | |
| CH616959A5 (enrdf_load_stackoverflow) | ||
| CH423095A (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes | |
| DE2415353A1 (de) | Verfahren zur herstellung von temperaturempfindlichen, nicht pathogenen mutanten von herpes simplex typ 2-viren und ihre verwendung zur herstellung von vaccinen | |
| Jawetz et al. | Studies on herpes simplex virus: VII. Immunological comparison of strains of herpes simplex | |
| DE1265916B (de) | Verfahren zur Herstellung eines Brucellose-Impfstoffs | |
| DE2805311A1 (de) | Respiratorische synzytial-vakzine | |
| DE3740182C2 (de) | Verfahren zur Herstellung eines Mutantenstamms von Bordetella bronchiseptica, der für einen Impfstoff für den Schutz von B. bronchiseptica-Infektionen nützlich ist, und daraus hergestellter AR-Impfstoff | |
| DE2921829C2 (enrdf_load_stackoverflow) | ||
| DE1966436C3 (de) | Verwendung einer Antigen-Immunserum-Kombination als Impfstoff | |
| DE2521050A1 (de) | Impfstoff und verfahren zur herstellung desselben | |
| DE2165401A1 (de) | Kombinations-Totvaccine | |
| DE1617568C (de) | Verfahren zur Abschwachung von Schwel necholeravirus in Schweinezellkulturen |